

Supplementary Table S1. Baseline characteristics and planned adjuvant chemotherapy choice (ITT population)

Characteristic	Chemotherapy alone (<i>N</i> = 1290)	Chemotherapy + bevacizumab (<i>N</i> = 1301)
Age, years, <i>N</i> (%)		
<40	253 (19.6)	231 (17.8)
40–64	916 (71.0)	952 (73.2)
≥65	121 (9.4)	118 (9.1)
Menopausal status, <i>N</i> (%)		
Premenopausal	665 (51.6)	676 (52.0)
Postmenopausal	625 (48.4)	625 (48.0)
ECOG performance status, <i>N</i> (%)		
0	1186 (91.9)	1202 (92.4)
1	94 (7.3)	98 (7.5)
2	1 (<0.1)	0
Missing	9 (0.7)	1 (<0.1)

Geographic region, *N* (%)

USA, Australia, Western Europe	792 (61.4)	783 (60.2)
Eastern Europe, Greece, Israel	160 (12.4)	148 (11.4)
South and Central America	37 (2.9)	22 (1.7)
Asia, New Zealand	301 (23.3)	348 (26.7)

Race, *N* (%)

White	968 (75.0)	932 (71.6)
Asian	280 (21.7)	333 (25.6)
Black	32 (2.5)	29 (2.2)
Other	10 (0.8)	7 (0.5)

Tumor size, cm (tumor stage),
N (%)

>0–<2 (T1)	457 (35.4)	482 (37.0)
2–<5 (T2)	759 (58.8)	755 (58.0)
≥5 (T3)	71 (5.5)	61 (4.7)
Missing	3 (0.2)	3 (0.2)

AJCC stage I, <i>N</i> (%)	388 (30.1)	382 (29.4)
Hormone receptor status ^a , <i>N</i> (%)		
ER and PgR negative	1224 (94.9)	1229 (94.5)
ER and/or PgR low	66 (5.1)	72 (5.5)
Positive axillary nodes ^a , <i>N</i> (%)		
0	814 (63.1)	824 (63.3)
1–3	326 (25.3)	322 (24.8)
≥4	150 (11.6)	155 (11.9)
Ductal/invasive histology, <i>N</i> (%)		
Grade 3 tumor, <i>N</i> (%)	895 (69.4)	912 (70.1)
Type of surgery ^a , <i>N</i> (%)		
Breast conserving	817 (63.3)	827 (63.6)
Mastectomy	473 (36.7)	474 (36.4)
Planned adjuvant chemotherapy ^a , <i>N</i> (%)		
Anthracycline	468 (36.3)	479 (36.8)

Anthracycline and taxane	756 (58.6)	752 (57.8)
Taxane	66 (5.1)	70 (5.4)
Hormonal therapy, <i>N</i> (%)	7 (0.5)	4 (0.3)
Radiotherapy, <i>N</i> (%)	953 (73.9)	952 (73.2)

^aStratification factor (data as recorded in interactive voice-response system).

AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; ITT, intent to treat; PgR, progesterone receptor.
